Mallinckrodt PLC (MNK) Given a $87.00 Price Target at Canaccord Genuity
Other analysts have also recently issued reports about the company. Jefferies Group LLC reiterated a buy rating and set a $70.00 price target on shares of Mallinckrodt PLC in a research report on Tuesday, June 20th. Morgan Stanley set a $65.00 price target on Mallinckrodt PLC and gave the stock a buy rating in a research report on Wednesday, May 31st. Deutsche Bank AG set a $68.00 price target on Mallinckrodt PLC and gave the stock a buy rating in a research report on Wednesday, May 31st. Mizuho restated a buy rating and issued a $73.00 target price on shares of Mallinckrodt PLC in a research report on Wednesday, May 31st. Finally, UBS AG set a $70.00 target price on Mallinckrodt PLC and gave the company a buy rating in a research report on Wednesday, May 24th. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and sixteen have given a buy rating to the company’s stock. Mallinckrodt PLC currently has an average rating of Buy and an average target price of $74.19.
Mallinckrodt PLC (MNK) traded up 2.01% on Monday, reaching $47.65. The company’s stock had a trading volume of 793,428 shares. The company’s market capitalization is $4.73 billion. Mallinckrodt PLC has a 52 week low of $38.80 and a 52 week high of $85.83. The firm’s 50 day moving average price is $43.52 and its 200-day moving average price is $46.37.
Mallinckrodt PLC (NYSE:MNK) last announced its quarterly earnings results on Monday, May 8th. The company reported $1.68 earnings per share for the quarter, topping analysts’ consensus estimates of $1.63 by $0.05. The business had revenue of $810.90 million for the quarter, compared to analysts’ expectations of $781.23 million. Mallinckrodt PLC had a return on equity of 16.33% and a net margin of 16.01%. The business’s quarterly revenue was down .6% on a year-over-year basis. During the same period in the prior year, the firm earned $2.01 EPS. On average, equities analysts predict that Mallinckrodt PLC will post $7.55 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: “Mallinckrodt PLC (MNK) Given a $87.00 Price Target at Canaccord Genuity” was originally published by Watch List News and is owned by of Watch List News. If you are reading this story on another publication, it was illegally stolen and republished in violation of US & international trademark and copyright law. The legal version of this story can be read at https://www.watchlistnews.com/mallinckrodt-plc-mnk-given-a-87-00-price-target-at-canaccord-genuity/1454479.html.
In related news, VP Coleman N. Lannum III acquired 1,968 shares of Mallinckrodt PLC stock in a transaction dated Friday, May 12th. The stock was acquired at an average cost of $46.20 per share, with a total value of $90,921.60. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Steven J. Romano acquired 1,000 shares of Mallinckrodt PLC stock in a transaction dated Friday, June 9th. The shares were bought at an average cost of $39.88 per share, with a total value of $39,880.00. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 5,818 shares of company stock valued at $248,608. Corporate insiders own 0.77% of the company’s stock.
Several large investors have recently added to or reduced their stakes in the company. Ladenburg Thalmann Financial Services Inc. raised its stake in Mallinckrodt PLC by 2.8% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,834 shares of the company’s stock valued at $143,000 after buying an additional 78 shares in the last quarter. Norges Bank bought a new stake in Mallinckrodt PLC during the fourth quarter valued at $45,574,000. Quadrature Capital Ltd bought a new stake in Mallinckrodt PLC during the fourth quarter valued at $408,000. UBS Asset Management Americas Inc. raised its stake in Mallinckrodt PLC by 1.3% in the fourth quarter. UBS Asset Management Americas Inc. now owns 1,306,580 shares of the company’s stock valued at $65,094,000 after buying an additional 16,571 shares in the last quarter. Finally, Kentucky Retirement Systems bought a new stake in Mallinckrodt PLC during the fourth quarter valued at $383,000. 96.37% of the stock is owned by institutional investors and hedge funds.
About Mallinckrodt PLC
Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.
Receive News & Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.